Details for Patent: 4,335,095

« Back to Dashboard

Summary for Patent: 4,335,095

Title:	Indium-111 oxine complex composition
Abstract:	An indium-111 preparation comprises a complex of indium-111 with a quinoline compound carrying an 8-hydroxyl group, e.g. oxine, present in an aqueous medium which also contains a surface active agent to prevent the complex from becoming bound to the surface of the vessel on autoclaving, and optionally a buffer to improve blood cell labelling efficiency. The surface active agent is preferably non-ionic, e.g. a polyoxyethylene sorbitan ester of a fatty acid. The buffer is preferably N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid.
Inventor(s):	James D. Kelly
Assignee:	GE Healthcare Ltd
Application Number:	US06/128,923
Patent Claim Types: see list of patent claims	Composition;

Drugs Protected by US Patent 4,335,095

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 4,335,095

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	7909867	Mar 21, 1979

International Family Members for US Patent 4,335,095

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Germany	3062496
European Patent Office	0017355
Japan	S55129229
Japan	S5914452